DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
"Perimeter OCT B-Series is the first system designed to combine AI with optical coherence tomography for margin assessment, with the aim of reducing the unacceptably high reoperation rates associated with BCS." $PINK $PINK.v $PYNKF $AI $NVDA #AI https://t.co/30HNtRIAiW
Intraoperative margin assessment remains a pressing challenge for surgeons and patients. Our investigational #AI technology could potentially be a powerful tool for margin assessment in the operating room and in real-time. https://t.co/t3pTsQ074h $PINK.V $PYNKF #aiinhealthcare https://t.co/aGykAzr3Br
Exciting news today! Patient enrollment in our pivotal clinical trial evaluating the use of Perimeter's next-gen B-Series OCT system with ImgAssist #AI during breast-conserving surgery is complete. https://t.co/t3pTsQ0ETP $PINK.V $PYNKF #breastcancer #clinicaltrials #medtech https://t.co/oZGx5qsHRs
Perimeter Medical Imaging AI has announced the closing of a non-brokered private placement on September 30. Chamath Palihapitiya, CEO of Social Capital and SC Master Holdings LLC, is the company's largest shareholder and lead investor in the offering. Additionally, Perimeter has completed patient enrollment in its pivotal clinical trial evaluating the B-Series OCT system with ImgAssist AI for breast-conserving surgeries on October 1. This investigational AI technology aims to address the challenge of intraoperative margin assessment, potentially reducing high reoperation rates. The company trades under the ticker $PINK.V.
